PROCEPT BioRobotics Co. (NASDAQ:PRCT) Shares Acquired by Two Sigma Investments LP

Two Sigma Investments LP increased its holdings in PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 91.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 353,716 shares of the company's stock after buying an additional 168,505 shares during the quarter. Two Sigma Investments LP owned about 0.68% of PROCEPT BioRobotics worth $28,481,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. SG Americas Securities LLC raised its holdings in shares of PROCEPT BioRobotics by 295.8% during the fourth quarter. SG Americas Securities LLC now owns 6,598 shares of the company's stock worth $531,000 after purchasing an additional 4,931 shares during the last quarter. Chicago Capital LLC raised its holdings in shares of PROCEPT BioRobotics by 44.5% during the fourth quarter. Chicago Capital LLC now owns 379,582 shares of the company's stock worth $30,564,000 after purchasing an additional 116,931 shares during the last quarter. Matisse Capital raised its holdings in shares of PROCEPT BioRobotics by 112.9% during the fourth quarter. Matisse Capital now owns 22,285 shares of the company's stock worth $1,794,000 after purchasing an additional 11,817 shares during the last quarter. Allspring Global Investments Holdings LLC raised its holdings in shares of PROCEPT BioRobotics by 218.1% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 401,210 shares of the company's stock worth $33,350,000 after purchasing an additional 275,071 shares during the last quarter. Finally, KBC Group NV raised its holdings in shares of PROCEPT BioRobotics by 46.0% during the fourth quarter. KBC Group NV now owns 2,236 shares of the company's stock worth $180,000 after purchasing an additional 705 shares during the last quarter. Hedge funds and other institutional investors own 89.46% of the company's stock.

PROCEPT BioRobotics Price Performance

Shares of NASDAQ:PRCT traded up $0.77 during midday trading on Tuesday, reaching $58.15. 176,764 shares of the company's stock traded hands, compared to its average volume of 977,150. PROCEPT BioRobotics Co. has a 1 year low of $47.04 and a 1 year high of $103.81. The company has a market cap of $3.22 billion, a P/E ratio of -29.82 and a beta of 1.10. The company has a debt-to-equity ratio of 0.21, a quick ratio of 5.07 and a current ratio of 6.02. The company has a fifty day simple moving average of $55.27 and a two-hundred day simple moving average of $70.16.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last announced its earnings results on Thursday, April 24th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.49) by $0.04. PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. The firm had revenue of $69.16 million for the quarter, compared to analyst estimates of $65.39 million. During the same quarter last year, the firm posted ($0.51) EPS. The business's revenue was up 55.5% on a year-over-year basis. Equities analysts predict that PROCEPT BioRobotics Co. will post -1.75 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on PRCT shares. Bank of America dropped their price objective on shares of PROCEPT BioRobotics from $104.00 to $84.00 and set a "buy" rating on the stock in a research note on Friday, April 25th. Wall Street Zen raised shares of PROCEPT BioRobotics from a "sell" rating to a "hold" rating in a research note on Saturday. Truist Financial dropped their price objective on shares of PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating on the stock in a research note on Friday, April 11th. Finally, Morgan Stanley dropped their price objective on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $90.00.

Insider Activity

In other PROCEPT BioRobotics news, CFO Kevin Waters sold 733 shares of the firm's stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total value of $41,824.98. Following the transaction, the chief financial officer now owns 107,991 shares in the company, valued at approximately $6,161,966.46. This trade represents a 0.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Reza Zadno sold 5,475 shares of the firm's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total value of $312,403.50. Following the completion of the transaction, the chief executive officer now owns 173,070 shares in the company, valued at $9,875,374.20. The trade was a 3.07% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 6,455 shares of company stock worth $368,322 in the last quarter. Corporate insiders own 6.60% of the company's stock.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).